Rakovina Therapeutics KT-5000AI Program Yields Potent ATR Inhibitor Hits in Early Screening

Rakovina Therapeutics KT-5000AI Program Yields Potent ATR Inhibitor Hits in Early Screening

VANCOUVER, British Columbia, July 23, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced meaningful progress in its AI-driven…

Rakovina KT-5000AI Yields Potent ATR Inhibitors in Screening - AI-Tech Park

Compounds developed through collaboration with Variational AI show targeted activity Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced meaningful progress in its AI-driven KT-5000AI program, advancing the development of precision ATR (Ataxia Telangiectasia and Rad3-re…